NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
| Revenue (TTM) | $725.39M |
| Gross Profit (TTM) | $560.38M |
| EBITDA | $-103.49M |
| Operating Margin | -2.05% |
| Return on Equity | -35.20% |
| Return on Assets | -6.80% |
| Revenue/Share (TTM) | $6.32 |
| Book Value | $3.12 |
| Price-to-Book | 4.87 |
| Price-to-Sales (TTM) | 2.18 |
| EV/Revenue | 2.035 |
| EV/EBITDA | -6.92 |
| Quarterly Earnings Growth (YoY) | -6.00% |
| Quarterly Revenue Growth (YoY) | 15.70% |
| Shares Outstanding | $116.92M |
| Float | $96.89M |
| % Insiders | 9.92% |
| % Institutions | 91.69% |
Volatility is currently expanding
Explore how NovoCure's (NVCR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
NovoCure generated record third-quarter net revenue of $193 million. Active glioblastoma patients grew 11% year over year to 4,730.
NovoCure NASDAQ: NVCR reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped lift active patient counts to a record level. The company also raised its full-year revenue and adjusted EBITDA outlook while acknowledging commercial headwinds for its newer Optune Pax therapy in the United States.
NovoCure (NVCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.33 per share a year ago.
NovoCure is undervalued at a $1.66B market cap, with its pipeline and FDA-approved products not fully reflected in its price. NVCR's revenue grew 16% YoY to $183.58M, with international sales and patient adoption accelerating, especially for new launches like Optune Pax. Valuation multiples are below sector medians (EV/Sales 2.05x vs. 3.66x), while the pipeline and upcoming Optune Mya launch offer significant upside.
NovoCure NASDAQ: NVCR outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference.
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVCR and any ticker you trade — then tracks every position and per-strategy win rate.
